Plain-English translation of NCT02103361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →This is a pregnancy registry—a tracking study—for women who have taken Stelara or Tremfya, which are medications used to treat psoriasis, psoriatic arthritis, and Crohn disease. Researchers want to understand whether these medications affect pregnancy outcomes and how babies grow and develop during their first year of life.
While these medications are used to help manage autoimmune conditions, doctors and patients need more information about their safety during pregnancy. This registry collects real-world experiences from women and their babies to build evidence about whether these treatments pose any risks.
You likely qualify if…
You likely don't qualify if…
You would share your medical records with the research team, including information about when you took the medication, details about your pregnancy, and your baby's health and development. Researchers will follow up to check on your baby's growth and development during the first year of life. The study involves no special visits or procedures—it's based on information you already have in your medical records.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Collaborators
The Organization of Teratology Information Specialists, Janssen Biotech, Inc.
Enrollment target
~200 participants
Started
November 2013
Primary completion
May 2030
Sex
Female only
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Diana Johnson, MS
University of California, San Diego
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.